{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T17:11:56Z","timestamp":1771693916889,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Norma Lee and Morton Funger Clinician Career Development Fund Award in Colon Cancer Research, Mayo Clinic"},{"name":"The Center for Clinical and Translational Science and the Center for Biomedical Discovery Pilot Awards for Team Science"},{"DOI":"10.13039\/100011542","name":"Center for Clinical and Translational Science, Mayo Clinic","doi-asserted-by":"publisher","award":["UL1 TR002377"],"award-info":[{"award-number":["UL1 TR002377"]}],"id":[{"id":"10.13039\/100011542","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mayo Clinic Department of Oncology FORIT Award"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2 TR002379"],"award-info":[{"award-number":["KL2 TR002379"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11523-025-01191-z","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T01:42:30Z","timestamp":1765417350000},"page":"117-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translational Relevance of the Genomic Landscape of KRASG12D-Mutant Colorectal and Pancreatic Cancers"],"prefix":"10.1007","volume":"21","author":[{"given":"Khalid","family":"Jazieh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina S.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin E.","family":"Fernandez-Zapico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9640-4055","authenticated-orcid":false,"given":"Hao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"1191_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47\u201352. https:\/\/doi.org\/10.1038\/nature16965.","journal-title":"Nature"},{"key":"1191_CR2","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.prp.2009.07.010","volume":"205","author":"J Neumann","year":"2009","unstructured":"Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205:858\u201362. https:\/\/doi.org\/10.1016\/j.prp.2009.07.010.","journal-title":"Pathol Res Pract"},{"key":"1191_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","volume":"19","author":"AR Moore","year":"2020","unstructured":"Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19:533\u201352. https:\/\/doi.org\/10.1038\/s41573-020-0068-6.","journal-title":"Nat Rev Drug Discov"},{"key":"1191_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"17","author":"L Buscail","year":"2020","unstructured":"Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17:153\u201368. https:\/\/doi.org\/10.1038\/s41575-019-0245-4.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"14","key":"1191_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143320","volume":"14","author":"A Koulouridi","year":"2022","unstructured":"Koulouridi A, Karagianni M, Messaritakis I, Sfakianaki M, Voutsina A, Trypaki M, et al. Prognostic value of KRAS mutations in colorectal cancer patients. Cancers (Basel). 2022;14(14):3320. https:\/\/doi.org\/10.3390\/cancers14143320.","journal-title":"Cancers (Basel)"},{"issue":"19","key":"1191_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193175","volume":"11","author":"H Shen","year":"2022","unstructured":"Shen H, Lundy J, Strickland AH, Harris M, Swan M, Desmond C, et al. KRAS G12D mutation subtype in pancreatic ductal adenocarcinoma: does it influence prognosis or stage of disease at presentation? Cells. 2022;11(19):3175. https:\/\/doi.org\/10.3390\/cells11193175.","journal-title":"Cells"},{"key":"1191_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.53588","volume":"8","author":"C Norton","year":"2025","unstructured":"Norton C, Shaw M, Rubnitz Z, Smith J, Soares H, Nevala-Plagemann C, et al. KRAS mutation status and treatment outcomes in patients with metastatic pancreatic adenocarcinoma. JAMA Netw Open. 2025;8:e2453588. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.53588.","journal-title":"JAMA Netw Open"},{"key":"1191_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/COC.0000000000000972","volume":"46","author":"J Liu","year":"2023","unstructured":"Liu J, Wang X, Sahin IH, Imanirad I, Felder SI, Kim RD, et al. Tumor response-speed heterogeneity as a novel prognostic factor in patients with metastatic colorectal cancer. Am J Clin Oncol. 2023;46:50\u20137. https:\/\/doi.org\/10.1097\/COC.0000000000000972.","journal-title":"Am J Clin Oncol"},{"key":"1191_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1917239.","journal-title":"N Engl J Med"},{"key":"1191_CR10","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-ND11","volume":"82","author":"H Purkey","year":"2022","unstructured":"Purkey H. Abstract ND11: discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers. Cancer Res. 2022;82:ND11. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-ND11.","journal-title":"Cancer Res"},{"key":"1191_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med. 2023;389:710\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2303810.","journal-title":"N Engl J Med"},{"key":"1191_CR12","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med. 2021;384:2382\u201393. https:\/\/doi.org\/10.1056\/NEJMoa2105281.","journal-title":"N Engl J Med"},{"key":"1191_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","volume":"30","author":"J Desai","year":"2024","unstructured":"Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, et al. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024;30:271\u20138. https:\/\/doi.org\/10.1038\/s41591-023-02696-8.","journal-title":"Nat Med"},{"key":"1191_CR14","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, et al. Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 2021;11:1913\u201322. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0365.","journal-title":"Cancer Discov"},{"key":"1191_CR15","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, Hoffman MT, Abbassi L, Li Z, Paradiso F, Parent BD, et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 2024;14:2135\u201361. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0177.","journal-title":"Cancer Discov"},{"issue":"269","key":"1191_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088.","journal-title":"Sci Signal"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01191-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01191-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01191-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:47:12Z","timestamp":1771692432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01191-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1191"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01191-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JT and SS: Guardant Health (employees and stockholders); HX: Cardiff Oncology (institution), Dynamicure (institution), BioNTech SE (institution), Qurient Therapeutics (institution), SparX Biopharmaceutical Corp (institution), and Xilio Therapeutics (institution). Khalid Jazieh, Katrina S. Pedersen, and Martin E. Fernandez-Zapico declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The first cohort (Guardant \u201cnational cohort\u201d) was a deidentified dataset made available by Guardant Health (Palo Alto, CA, USA) for research purposes, with approval from the Advarra Institutional Review Board (Pro00034566). The second cohort consisted of patients with advanced or metastatic PDAC or CRC tested with Guardant360 assays at the Mayo Clinic from January 2016 to June 2023 (\u201cMayo cohort\u201d), approved by the institutional review board (23-005258).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate\/Consent to Publish"}},{"value":"Data, analytic methods, and study materials will or will not be made available to other researchers upon request to corresponding author Dr. Hao Xie.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Khalid Jazieh: conception, design, data analysis, and manuscript preparation; Jill Tsai: conception, design, data analysis, and manuscript review; Sheila Solomon: data analysis and manuscript review; Mojun Zhu and Katrina S. Pedersen: manuscript review; Martin E. Fernandez-Zapico: design and manuscript review; Hao Xie: conception, design, and manuscript preparation and review.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}